报价延迟最少15分钟:2025/09/17 05:54 EDT
盘前时段
|
||||
|
120.01 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.25/1.87
|
|
企业价值
7.07B
|
| 资产负债 |
|
每股账面净值
36.65
|
| 现金流量 |
|
现金流量率
0.02
|
| 损益表 |
|
收益
29.36M
|
|
每股收益
11.91
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/17 05:54 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively. |
